BIORYA Observatory · Active

Rhodiola rosea: adaptogenic resilience, studied for 60 years

Used by the Vikings, Siberian shepherds and Soviet cosmonauts, Rhodiola rosea is the most rigorously studied adaptogen in Europe. Here is exactly what it does to the body, at what dose, and what more than 180 clinical trials show.

← Back to the Observatory

"Adaptogen" is not a marketing word. The term was defined by N. Lazarev (1947) to describe substances that non-specifically raise an organism's capacity to resist stress. Rhodiola rosea is one of the three adaptogens officially recognised by the EMA (European Medicines Agency, 2012 monograph).

Rhodiola roots in a natural setting
Rhodiola rosea grows naturally at 1,800–2,700 m altitude in Siberia and Scandinavia. Its root concentrates the active compounds.

1. Botanical ID card

Scientific nameRhodiola rosea L.
FamilyCrassulaceae
Part usedRhizome (root)
Standardisation3% rosavins + 1% salidroside
EU statusEMA — recognised traditional use
Historical use≥ 1,200 years (Tibet, Siberia manuscripts)

2. Active compounds — who does what?

Salidroside

Phenolic glycoside. Main target for CNS effects. Neuroprotective and anti-fatigue effects documented in more than 80 studies (Ishaque 2012).

Rosavins (rosavin, rosin, rosarin)

Specific to R. rosea (absent from other Rhodiola species). They modulate the monoaminergic system and the HPA axis.

Tyrosol & p-tyrosol

Precursors of salidroside. Antioxidant and anti-inflammatory activity (Calcabrini 2010).

Flavonoids (rhodionin, rhodiosin)

Reinforce the adaptogenic effect by modulating cellular signalling under oxidative stress.

3. Mechanism of action — what changes in the body

Rhodiola is not a stimulant. It acts as a regulator of the HPA axis (Hypothalamic-Pituitary-Adrenal) and the sympathetic nervous system:

  • ↓ Morning cortisol by 23% on average over 28 days at 400 mg/day (Olsson 2009).
  • Inhibition of COMT and MAO → ↑ availability of norepinephrine, dopamine, serotonin in the brain.
  • ↑ Mitochondrial ATP and ↓ lipid peroxidation (action on cellular fatigue).
  • HSP-70 modulation (heat-shock protein) — cellular protection under stress.
  • Brain tissue protection against oxidative stress (Panossian 2010, PI3K/Akt study).

4. What major clinical trials show

−50 %of burnout score (MBI) after 12 weeks at 400 mg/day (Kasper 2017, RCT)
−42 %on CGI-S (clinical severity) in 8 weeks — work-related stress (Edwards 2012, n=101)
+50 %cognitive performance under mental fatigue in on-call medical residents (Spasov 2000, n=40)
−54 %of self-reported mental fatigue after 4 weeks at 576 mg/day (Olsson 2009)

5. Effective dosage — the clinical window

GoalValidated doseTime to onset
Work-related stress / burnout200–400 mg/day2–4 weeks
Chronic mental fatigue200–600 mg/day4–8 weeks
Acute cognitive performanceSingle 200 mg dose, 1 h before30–60 min
Observed effective plateau≈ 680 mg/day

All cited studies use an extract standardised to 3% rosavins and 1% salidroside (SHR-5 type, developed in Sweden). Non-standardised extracts may be 5 to 10 times less concentrated in active principles.

6. Why BIORYA chose it

In CALM AUTHORITY, Rhodiola brings the long-term resilience dimension — where L-theanine soothes immediately, Rhodiola rebuilds the capacity to absorb. It is the active for demanding days, cycles of pressure, periods where you have to hold without burning out. Paired with the 60-second ritual, it fits into a steady, measurable baseline day after day.

7. Cited studies

  • Kasper S., Dienel A. (2017). Multicenter open-label exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms. Neuropsychiatric Disease and Treatment.
  • Edwards D. et al. (2012). Therapeutic Effects and Safety of Rhodiola rosea Extract WS®1375 in Subjects with Life-stress Symptoms — a RCT. Phytotherapy Research.
  • Olsson E. M. G. et al. (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Medica.
  • Spasov A. A. et al. (2000). A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students. Phytomedicine.
  • Panossian A., Wikman G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals.
  • Ishaque S. et al. (2012). Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complementary and Alternative Medicine.
  • EMA (2012). Community herbal monograph on Rhodiola rosea L., rhizoma et radix. European Medicines Agency.

Want a precise BIORYA protocol matched to your profile?